ArticleEJHaem2024

Identifying clinical response to daratumumab therapy in relapsed/refractory multiple myeloma using a patient-derived in vitro model.

Niels van Nieuwenhuijzen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.